ACAD
$24.63
Acadia Pharmaceutica
$.64
2.67%
ACAD
Earnings Whisper ®
N/A
2nd Quarter June 2023
Consensus:  ($0.21)
Revenue:  $138.18 Mil
Monday
Aug 7
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACAD reports earnings?
Beat
Meet
Miss

Where is ACAD's stock price going from here?
Up
Flat
Down
Stock chart of ACAD
Analysts
Summary of analysts' recommendations for ACAD
Score
Grade
Pivots
Resistance
$26.08
$25.44
$25.03

$24.39

Support
$23.99
$23.35
$22.94
Tweet
Growth
Description
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalRegeneron PharmaceuticalsJohnson & JohnsonEli LillyMerck & Co.Bristol-Myers SquibbArray TechnologiesUltragenyx PharmaceuticalPfizer